



The US Oncology Network's Public Policy & Reimbursement Committee Submits Comments to FTC on PBM Practices Impacting Community Cancer Care

The Network encourages the FTC to move forward with study examining PBM pricing and contractual practices

Earlier today, Dr. Debra Patt, physician at Texas Oncology and Chair of The Network's Public Policy and Reimbursement Committee, submitted comments in response to the Federal Trade Commission's (FTC) Request For Information (RFI) on the business practices of pharmacy benefit managers (PBMs) and their impact on independent pharmacies and consumers.

In its response to the RFI, The Network emphasized how PBM interference with patient care has only increased as the nation's largest insurers, PBMs and specialty pharmacies have grown and consolidated. The Network's comments focused on the following PBM practices and their impact on community oncology practices and cancer patients:

- Narrow networks and steerage to affiliated specialty pharmacies for oral oncolytics and physician-administered drugs
- Utilization management policies driven by cost containment goals rather than patient outcomes

The Network called on the FTC to move forward with a study examining PBM pricing and contractual practices.

To read The Network's comments in their entirety, [CLICK HERE](#).

To read the FTC's Request For Information, [CLICK HERE](#).